Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

BioHedge, at least 50% remission rate was observed in all three cohorts (17 patients). Here's the abstract.

"The BRI-UP/UPS study (open-label; 3 sequential dose-escalation cohorts: 50mg, 100mg, 200mg; total of 17 patients)–favorable results were observed across the BRI cohorts at Day 42, including evidence of Clinical Remission (with endoscopic response) in at least half of patients and improved patient quality-of-life."

http://www.ddtwc.com/abstracts.php

Since we already knew 6 out of 12 patients achieved remission in the first two cohorts, the possible scenarios for the third cohort are:

3 out of 5 remission -> 9 out of 17 (53%)

4 out of 5 remission -> 10 out of 17 (59%)

5 out of 5 remission -> 11 out of 17 (65%)